ChariotMS is a clinical trial to investigate whether Cladribine (MAVENCLAD®) - an established MS treatment, can preserve upper limb function in people who have largely lost the ability to walk (EDSS 6.5-8.5).
This is affects some 44% of all people with MS in the UK
ChariotMS is a groundbreaking trial:
It's the the first trial for wheelchair users who are usually excluded from trials and so have few licenced treatments.
It's the first uk Clinical Trial with no upper age limit.